Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 7/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3801732 | 0.89 | ALOX5 (0.38) | ALOX5PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL332537 | 0.81 | ALOX5 (0.74) | ALOX5PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL332725 | 0.81 | ALOX5 (0.53) | ALOX5PIK3CDKMT2ANAAA | |
| SCHEMBL3655644 | 0.76 | ALOX5 (0.42) | ALOX5LRRK2NAAA | |
| SCHEMBL3660567 | 0.75 | ALOX5 (0.46) | ALOX5ICMTPIK3CDNAAA | |
| SCHEMBL333246 | 0.71 | ALOX5 (0.46) | ALOX5ICMTNAAA | |
| SCHEMBL333240 | 0.70 | ALOX5 (0.43) | ALOX5PIK3CDKMT2ANAAA | |
| SCHEMBL332522 | 0.70 | ALOX5 (0.41) | ALOX5ICMTPIK3CDKMT2A | |
| SCHEMBL332555 | 0.69 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL332240 | 0.68 | ALOX5 (0.76) | ALOX5PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2225229-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | Pfizer Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | ALOX5 1/4885ICMT 3459/4885PDE4A 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.